Kazia Therapeutics (KZIA) supplements prospectus, registers 10.7M ADS; chair resigns

Rhea-AI Filing Summary

Kazia Therapeutics Limited files a prospectus supplement registering 10,700,211 American Depositary Shares, representing 5,350,105,500 Ordinary Shares, and furnishes a Form 6-K dated March 31, 2026. The supplement attaches an investor presentation and fact sheet dated March 27, 2026 and notes the ADS last sale price of $7.31 per ADS.

The Form 6-K reports the resignation of Chairman Bryce Carmine effective March 31, 2026, a reduction in Board size from four to three directors, appointment of Ebru Davidson to the Audit, Risk and Governance Committee, and shareholder re-election of Steven Coffey at the AGM.

Insights

Corporate Governance Analyst

Board chair resigns; board reduced to three members.

The filing states that Bryce Carmine resigned as Chair and from all committees effective March 31, 2026. The Board accepted the resignation and appointed Ebru Davidson to the Audit, Risk and Governance Committee.

The company reduced board size from four to three directors; future board composition and any committee reconfigurations are not detailed in the excerpt.

Equity Capital Markets Analyst

Prospectus supplement registers 10.7M ADS (5.35B ordinary-share equivalent).

The prospectus supplement explicitly lists 10,700,211 ADS representing 5,350,105,500 Ordinary Shares and attaches a March 27, 2026 investor presentation and fact sheet as exhibits.

The ADSs trade on Nasdaq under the symbol KZIA; the last reported sale price shown is $7.31 per ADS.

Key Figures

ADS registered: 10,700,211 ADS Ordinary share equivalent: 5,350,105,500 Ordinary Shares Last sale price: $7.31 per ADS +2 more

5 metrics

ADS registered 10,700,211 ADS Prospectus supplement

Ordinary share equivalent 5,350,105,500 Ordinary Shares Representation of ADSs

Last sale price $7.31 per ADS Last reported sale price on Nasdaq as of March 30, 2026

Board size reduced from 4 to 3 Directors Effective upon resignation of Chairman

AGM vote FOR 1,050,412,780 votes Re-election of Steven Coffey

Key Terms

American Depositary Shares (ADSs), Prospectus Supplement, Form 6-K, Audit, Risk and Governance Committee

4 terms

American Depositary Shares (ADSs) financial

"10,700,211 American Depositary Shares representing 5,350,105,500 Ordinary Shares"

A U.S.-listed certificate that stands for a specific number of shares in a non‑U.S. company held by a U.S. bank, making the foreign stock tradable on American exchanges in dollars. Think of it like a local voucher that represents ownership of an overseas product — it lets U.S. investors buy and sell foreign companies without handling foreign currency or foreign brokerage accounts, but it can affect dividends, voting rights, fees, liquidity and exposure to currency and regulatory differences.

Prospectus Supplement regulatory

"This prospectus supplement is being filed to update and supplement the information"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

Form 6-K regulatory

"This prospectus supplement updates and supplements the information in the Prospectus with the information contained in our Form 6-K"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

Audit, Risk and Governance Committee governance

"appointed to the Audit, Risk and Governance Committee of the Board"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/31/2026 - 06:59 PM Learn about SEC filing dates

FAQ

What does Kazia Therapeutics' prospectus supplement register (KZIA)?

It registers 10,700,211 ADS. The supplement states these ADS represent 5,350,105,500 Ordinary Shares and attaches a March 27, 2026 investor presentation and fact sheet as exhibits to the filing.

Who resigned from Kazia Therapeutics' board in March 2026 (KZIA)?

Chairman Bryce Carmine resigned effective March 31, 2026. The filing says his resignation was not due to any disagreement with the company and he left all board committees; the Board accepted his resignation.

What were the AGM voting results for Steven Coffey (KZIA)?

Steven Coffey was re-elected by shareholders. The reported vote tally was 1,050,412,780 FOR, 3,637,588 AGAINST, and 1,289,127 ABSTAIN, as shown in the Form 6-K.

What exhibits did Kazia furnish with its March 31, 2026 Form 6-K (KZIA)?

Two exhibits were furnished: an investor presentation dated March 27, 2026 (Exhibit 99.1) and a fact sheet dated March 27, 2026 (Exhibit 99.2), both attached to the Form 6-K.

Filed Pursuant to Rule 424(b)(3)
Registration No. 333-292303

PROSPECTUS SUPPLEMENT

(to Prospectus dated December 23, 2025)

10,700,211 American Depositary Shares representing

5,350,105,500

Ordinary Shares

Kazia Therapeutics Limited

This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 23, 2025 (the “Prospectus”), which forms a part of our Registration Statement on Form F-1 (Registration No. 333-292303), with the information contained in our current report on Form 6-K, furnished to the Securities and Exchange Commission on March 31, 2026 (the “March 31, 2026 Form 6-K”). Accordingly, we have attached the March 31, 2026 Form 6-K to this prospectus supplement.

This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.

The ADSs are listed on The Nasdaq Capital Market (“Nasdaq”) under the symbol “KZIA.” On March 30, 2026, the last reported sale price of the ADSs on Nasdaq was $7.31 per ADS.

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 9 of the Prospectus and the “Risk Factors” in “Item 3. Key Information-D. Risk Factors” of our most recent Annual Report on Form 20-F, which is incorporated by reference in the Prospectus, as well as in any other recently filed reports and, if any, in any applicable prospectus supplement.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is March 31, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION 

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of March 2026

Commission File Number: 000-29962

Kazia Therapeutics Limited.

(Exact Name of Registrant as Specified in Its Charter)

Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒        Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

Departure of Director

This report on Form 6-K (the “Report”) contains information regarding a change to the board of directors (the “Board”) of Kazia Therapeutics Limited (the “Company”). On March 26, 2026, Bryce Carmine, the current Chairman of the Board, notified the Board of his intent to retire. The Board accepted his resignation from the Board and all of its committees, including his roles as Chair of the Board and member of the Remuneration and Nomination Committee and Audit, Risk and Governance Committee, effective March 31, 2026.

Mr. Carmine’s resignation was not the result of any disagreement between him and the Company on any matter relating to the Company’s operations, policies or practices. Effective upon Mr. Carmine’s resignation, Ms. Ebru Davidson was appointed to the Audit, Risk and Governance Committee of the Board and the size of the Company’s Board of Directors was reduced from four to three Directors.

Results of Annual General Meeting

As scheduled, the Company held its Annual General Meeting (the “AGM”) at 9.00 a.m., Sydney time, on March 25, 2026, online at https://kaziatherapeutics.verovoting.com.au. At the AGM, the Company’s shareholders voted on one resolution with respect to the re-election of Steven Coffey as a director of the Company, which is listed below and was described in more detail in the Company’s Notice of Annual General Meeting and accompanying Explanatory Statement, which are available electronically on the “For Investors” section of the Company’s website.

Resolution 1 – Re-election of Steven Coffey as Director

The re-election of Steven Coffey as a director of the Company was approved by the Company’s shareholders. The results of the approval were as follows:

		FOR		AGAINST		ABSTAIN
VOTES		1,050,412,780		3,637,588		1,289,127

Investor Presentation and Fact Sheet

The Company is furnishing with this Report on Form 6-K (i) its corporate presentation, dated March 27, 2026, as Exhibit 99.1 and (ii) its fact sheet, dated March 27, 2026, as Exhibit 99.2.

The information in this Report, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

EXHIBIT INDEX

The following exhibits are furnished as part of this Form 6-K:

Exhibit		Description
99.1		Investor Presentation dated March 27, 2026.
99.2		Fact Sheet dated March 27, 2026.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Kazia Therapeutics Limited.
	By:	/s/ John Friend
	Name:	John Friend
	Title:	Chief Executive Officer
Date: March 31, 2026

2